Lakefront Biotherapeutics (LKFT)
NASDAQ:LKFT
Want to see LKFT full AI Analyst Report?
Top Page
Lakefront Biotherapeutics
(NASDAQ:LKFT)
Select Model
Select Model
Rating:59Neutral
Price Target:
$30.00
▲(2.46% Upside)
Action:Reiterated
Date:05/09/26
The score is driven primarily by strong financial flexibility (very strong balance sheet) but materially constrained by continued cash burn and negative free cash flow. Technicals are weak with the stock below key moving averages and negative MACD, while valuation is not especially supportive (P/E ~29 and no dividend). The earnings call adds moderate support due to strategic progress and funding visibility, tempered by significant 2026 cash outflows and execution risk.
Positive Factors
Strong cash and investments
A nearly EUR 3.0bn cash/investment base gives the company durable financial flexibility to fund R&D, co‑fund the Ouro transaction, pursue BD opportunities, and absorb near‑term losses without immediate refinancing, materially reducing short‑term solvency risk.
Negative Factors
Persistent negative cash generation
Sustained negative operating and free cash flow forces reliance on the balance sheet and external funding for operations and development. Even with a strong cash buffer, continued cash burn elevates dilution or asset‑sale risk if clinical or transaction timelines slip.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash and investments
A nearly EUR 3.0bn cash/investment base gives the company durable financial flexibility to fund R&D, co‑fund the Ouro transaction, pursue BD opportunities, and absorb near‑term losses without immediate refinancing, materially reducing short‑term solvency risk.
Read all positive factors
Lakefront Biotherapeutics (LKFT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.79B
Dividend YieldN/A
Average Volume (3M)110.39K
Price to Earnings (P/E)3.3
Beta (1Y)0.76
Revenue Growth292.60%
EPS GrowthN/A
CountryUS
Employees452
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)7.42
Shares Outstanding65,897,070
10 Day Avg. Volume99,472
30 Day Avg. Volume110,389
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.57
Price to Sales (P/S)1.65
P/FCF Ratio-6.76
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue1.48
Enterprise Value/Gross Profit1.51
Enterprise Value/Ebitda3.87
Forecast
1Y Price Target
$25.00Price Target Upside-14.62% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering2
EPS Forecast (FY)-3.1
Revenue Forecast (FY)$26.65M
Lakefront Biotherapeutics Business Overview & Revenue Model
Company Description
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in der...
How the Company Makes Money
Galapagos makes money primarily through collaboration-based revenues and, when applicable, product-related economics from partnered programs. Key revenue streams can include (i) upfront payments received when entering strategic research or develop...
Lakefront Biotherapeutics Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
92
Very Positive
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.04B | 1.11B | 275.65M | 239.72M | 241.25M | 484.85M |
| Gross Profit | 1.02B | 1.08B | 240.79M | 239.72M | 241.25M | 483.22M |
| EBITDA | 398.09M | 358.96M | 43.33M | 51.04M | 3.87M | -100.93M |
| Net Income | 488.78M | 320.88M | 74.08M | 211.70M | -217.99M | -125.42M |
Balance Sheet | ||||||
| Total Assets | 3.37B | 3.41B | 4.14B | 4.36B | 4.73B | 5.19B |
| Cash, Cash Equivalents and Short-Term Investments | 2.98B | 3.00B | 3.12B | 3.68B | 4.09B | 4.70B |
| Total Debt | 6.43M | 6.92M | 11.72M | 9.60M | 21.90M | 26.86M |
| Total Liabilities | 119.06M | 170.65M | 1.24B | 1.56B | 2.21B | 2.55B |
| Stockholders Equity | 3.25B | 3.24B | 2.90B | 2.80B | 2.53B | 2.64B |
Cash Flow | ||||||
| Free Cash Flow | -310.33M | -271.31M | -402.14M | -425.24M | -537.49M | -561.71M |
| Operating Cash Flow | -301.60M | -257.46M | -320.03M | -405.97M | -500.54M | -503.83M |
| Investing Cash Flow | 265.57M | 288.81M | 220.60M | 71.19M | -1.25B | 541.24M |
| Financing Cash Flow | -2.77M | -3.27M | -4.92M | -5.00M | -1.49M | -3.88M |
Lakefront Biotherapeutics Technical Analysis
Positive
29.28
Price Trends
28.39
Negative
30.94
Negative
31.68
Negative
Market Momentum
-0.22
Negative
51.27
Neutral
44.32
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LKFT, the sentiment is Positive. The current price of 29.28 is above the 20-day moving average (MA) of 27.61, above the 50-day MA of 28.39, and below the 200-day MA of 31.68, indicating a neutral trend. The MACD of -0.22 indicates Negative momentum. The RSI at 51.27 is Neutral, neither overbought nor oversold. The STOCH value of 44.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LKFT.
Lakefront Biotherapeutics Risk Analysis
Lakefront Biotherapeutics disclosed 79 risk factors in its most recent earnings report. Lakefront Biotherapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
We are dependent on the transfer of the Jyseleca business, including the European and UK Marketing Authorizations, the commercial, medical affairs and development activities for Jyseleca and approximately 400 Galapagos positions in 14 European countries, to Alfasigma. Q4, 2023
2.
Risks associated to the legal uncertainty around the Unitary patent court in Europe Q4, 2023
3.
If approved, our investigational products regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway. Q4, 2023
Lakefront Biotherapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $4.20B | -198.04 | -26.79% | ― | 96.03% | 82.27% | |
59 Neutral | $1.79B | 3.26 | 16.28% | ― | 292.60% | ― | |
59 Neutral | $1.84B | -3.59 | -54.32% | ― | 11.07% | 32.35% | |
58 Neutral | $2.53B | -53.70 | -14.19% | ― | 128.99% | 58.46% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $1.65B | -4.00 | -34.11% | ― | 78.34% | -161.91% | |
47 Neutral | $2.69B | -11.33 | -36.95% | ― | ― | -68.57% |
* Healthcare Sector Average
LKFT
Lakefront Biotherapeutics
28.11
0.38
1.37%
AGIO
Agios Pharma
28.79
-5.54
-16.14%
TVTX
Travere Therapeutics
46.18
30.86
201.44%
IRON
Disc Medicine
71.11
21.09
42.16%
TARS
Tarsus Pharmaceuticals
60.34
16.42
37.39%
RXRX
Recursion Pharmaceuticals
3.80
-1.69
-30.78%
Lakefront Biotherapeutics Corporate Events
Galapagos Rebrands as Lakefront Biotherapeutics and Reshapes Portfolio Around Gilead–Ouro Autoimmune Deal
May 6, 2026
On May 6, 2026, Galapagos reported first-quarter 2026 results and detailed a strategic pivot centered on a binding collaboration with Gilead Sciences tied to Gilead’s acquisition of U.S.-based Ouro Medicines. The deal will give Galapagos an ...
Galapagos Shareholders Approve Name Change to Lakefront Biotherapeutics and Broad Governance Overhaul
Apr 29, 2026
On 28 April 2026, Galapagos NV held its Annual and Extraordinary Shareholders’ Meetings, where investors approved the 2025 annual and remuneration reports, discharged directors and the auditor from liability, and confirmed a broad refresh of...
Galapagos Strikes New Gilead Deal to Co-Develop Gamgertamig and Unlock $500 Million for Strategic Moves
Mar 31, 2026
On March 31, 2026, Galapagos announced a binding framework agreement with Gilead Sciences tied to Gilead’s planned $1.675 billion acquisition of US biotech Ouro Medicines, securing shared rights to Ouro’s T cell engager portfolio for a...
Galapagos Files 2025 Annual Report and Calls April 28 Meetings on Rebranding and Share Buyback
Mar 30, 2026
Galapagos NV has published its 2025 annual report and filed its related documentation with the U.S. SEC on March 30, 2026, ahead of its Annual and Extraordinary Shareholders’ Meetings scheduled in Mechelen, Belgium, on April 28, 2026. The ma...
Galapagos Seeks Strategic Tie-Up With Gilead Around Ouro Medicines Deal and T Cell Engager OM336
Mar 24, 2026
On March 23, 2026, Galapagos announced it is in advanced talks with long-time partner Gilead Sciences over a new strategic collaboration tied to Gilead’s planned $1.675 billion acquisition of Ouro Medicines, a T cell engager specialist. The ...
Galapagos Discloses Bank of America’s Stake Drop Below 5% Threshold
Mar 17, 2026
On March 17, 2026, Galapagos NV reported that it had received a transparency notification from Bank of America Corporation under Belgian disclosure rules, following a reduction in Bank of America’s economic exposure to the company. The notif...
Galapagos Discloses Bank of America Crossing 5% Ownership Threshold in March 2026
Mar 10, 2026
On March 10, 2026, Galapagos reported that it had received transparency notifications from Bank of America Corporation under Belgian disclosure rules, detailing recent changes in Bank of America’s exposure to Galapagos shares. The filings sh...
Galapagos Launches Major 2026 Subscription Right Plan, Expanding Equity Incentive Pool
Mar 6, 2026
On March 6, 2026, Galapagos NV’s board approved “Subscription Right Plan 2026,” creating 1,750,000 subscription rights for current and potential future employees, each entitling the holder to subscribe to one new Galapagos share....
Galapagos Names New Chief HR Officer to Support Ongoing Corporate Transformation
Mar 5, 2026
On March 5, 2026, Galapagos announced it had appointed seasoned life sciences human resources executive Tania Philipp as Chief Human Resources Officer, effective March 4, 2026, and added her to its Management Committee. She replaces outgoing HR ch...
Galapagos Discloses Bank of America Crossing 5% Shareholding Threshold
Mar 4, 2026
On March 4, 2026, Galapagos reported that it had received transparency notifications from Bank of America Corporation, revealing changes in the bank’s position in Galapagos’ voting rights and equivalent financial instruments during lat...
Galapagos Posts 2025 Profit and Accelerates Strategic Exit from Cell Therapy
Feb 24, 2026
Galapagos reported its full-year 2025 results on February 23, 2026, highlighting a strategic reset centered on winding down its cell therapy business and pivoting to business development-led growth. The company closed 2025 with about €3.0 bi...
Galapagos Adds Industry Veteran Paulo Fontoura to Board as Independent Director
Feb 19, 2026
Galapagos announced on February 19, 2026, that it has co-opted Dr. Paulo Fontoura as a Non-Executive Independent Director to its Board, effective February 9, 2026. He replaces Dr. Susanne Schaffert, who stepped down from the Board on November 1, 2...
Galapagos Discloses Bank of America Crossing 5% Voting Rights Threshold
Feb 10, 2026
On February 10, 2026, Galapagos reported that Bank of America Corporation and its affiliates repeatedly crossed the 5% transparency threshold in the company’s voting rights in early February, triggering a series of regulatory notifications u...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.